Oncology

Congress Materials – International Myeloma Society (IMS 2026)

2026 International Myeloma Society | Sep 23-26 | Glasgow, United Kingdom

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

5-Year Sustained Minimal Residual Disease (MRD) Negativity and Survival With Daratumumab Maintenance (D-Maint) in Transplant-Eligible (TE) NDMM: CASSIOPEIA Registry

Jill Corre, Pieter Sonneveld, Sonja Zweegman, Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Bertrand Arnulf, Michel Delforge, Thomas Dejoie, Lionel Karlin, Nathalie Meuleman, Laure Vincent, Jean-Richard éveillard, Cécile Sonntag, Mohamad Mohty, Xavier Leleu, Margaret Macro, Yuping Chen, Alba Tuozzo, Carla de Boer, Fredrik Borgsten, Melissa Rowe, Ariane Boumendil, Philippe Moreau

This document will be available on Sep 24th 2026

Cost per Responder for Teclistamab-Daratumumab Versus Daratumumab, Pomalidomide, Dexamethasone (DPd), and Daratumumab, Bortezomib, Dexamethasone (DVd) in Relapsed Refractory Multiple Myeloma Patients

Ryan Haumschild, Donald C. Moore, Maithili Deshpande, Sharvari Bhurke, Arielle Bensimon, Joseph A. Goble, Tonya Le Blanc, Shuchita Kaila, Niodita Gupta-Werner, Lucio Gordan

This document will be available on Sep 23rd 2026

Efficacy and Safety of Daratumumab Plus VCd in Newly Diagnosed Amyloid Light-Chain Amyloidosis With Cardiac Involvement: A Pooled Analysis of Asian Patients From AMY2009 and AMY3001

Jin Lu, Minghui Zhao, Yu Wu, Xiaonong Chen, Zhen Cai, Fude Zhou, Kenshi Suzuki, Kihyun Kim, Chihiro Shimazaki, Jin Seok Kim, Takayuki Ikezoe, Chang Ki Min, Shinsuke Iida, Nagaaki Katoh, Tomoaki Fujisaki, Ho Jin Shin, NamPhuong Tran, Matteo Loi, Yishen Yang, Jianmin Zhuo, Xue Gai, Kwang wei Wu, Bijie Xun, Yulin Gong

This document will be available on Sep 24th 2026

eMMpower-CART: Real-World Insights Into Early-Line Cilta-Cel Outcomes in Multiple Myeloma (MM)

Binod Dhakal, Hamza Hashmi, Carlyn Rose Tan, Amir Ali, Baylee Bryan, Matthew Pianko, Cindy Varga, Jennifer M. Ahlstrom, Saurabh Nagar, Yuehan Zhang, Jinghua He, Sang Kyu Cho, Justin Hayne, Victoria Alegria, Shuchita Kaila, Zaina Qureshi, Rafael Fonseca

This document will be available on Sep 25th 2026

First Results of a Noninterventional, Prospective, Postauthorization Safety Study (PASS) of Ciltacabtagene Autoleucel (Cilta-Cel) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

Hermann Einsele, Vladan Vučinić, Jayr Schmidt Filho, Christof Scheid, Christian R. Schultze-Florey, Raphael Teipel, Leo Hansmann, Bastian Von Tresckow, Maximilian Merz, Marc-Steffen Raab, Phillip Scheinberg, Katja Weisel, Silva Koskinen, Sandra Toro-Silva, Arham Jamal, Imène Haddad, Mukta Sharma, Yan Wang, Keqin Qi, Natalia Martin Suñe, Vrinda Mahajan, Tamar Lengil, Maria T. Krauth, Ralph Wäsch

This document will be available on Sep 23rd 2026

Long-Term (≥5-Year) Remission and Survival With Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: CARTITUDE-2 Cohort A

Adam D. Cohen, María-Victoria Mateos, Yaël C. Cohen, Michel Delforge, Mounzer E. Agha, Jens Hillengass, Christof Scheid, Sébastien Anguille, Katja Weisel, Marc S. Raab, Paula Rodríguez-Otero, Shambavi Richard, Huabin Sun, Ioanna Tsakos, Kevin C. De Braganca, Lee Jablow, Christina Corsale, Helen Varsos, Man Zhao, Ana Caroline Costa Sa, Nikoletta Lendvai, Nitin Patel, Christopher del Corral, Hermann Einsele, Niels W.C.J. van de Donk

This document will be available on Sep 25th 2026

Long-Term Outcomes with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Versus VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) in the Phase 3 PERSEUS Study

Pieter Sonneveld, Mario Boccadoro, Meletios A. Dimopoulos, Hermann Einsele, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels WCJ van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Yanfang Liu, Diego Vieyra, Alba Tuozzo, Carla J. de Boer, Fredrik Borgsten, Anna Sitthi-Amorn, Melissa Rowe, Robin Carson, Paula Rodríguez-Otero, Joan Bladé Creixenti, Philippe Moreau

This document will be available on Sep 25th 2026

Matching-Adjusted Indirect Treatment Comparison of Teclistamab Monotherapy (Tec) vs Belantamab With Pomalidomide and Dexamethasone (BPd) for Early-Line Relapsed or Refractory Multiple Myeloma (RRMM)

Khalid F. Saja, Sandhya Nair, Nina Kim, Mary Slavcev, Eric Ammann, Priya Shah, Margaret Doyle, Nizar J Bahlis

This document will be available on Sep 23rd 2026

Matching-Adjusted Indirect Treatment Comparison of Teclistamab With Daratumumab (Tec-Dara) vs Belantamab With Bortezomib and Dexamethasone (BVd) for Early-Line Relapsed/Refractory Multiple Myeloma

Gary Simmons, Mi Jun Keng, Sandhya Nair, Mary Slavcev, Maggie O’Hara, Eric Ammann, Margaret Doyle, Niodita Gupta Werner, Weili Sun, Wouter Plattel

This document will be available on Sep 23rd 2026

MRD-Guided Frontline T-Cell Redirection Therapy for Newly Diagnosed High-Risk Multiple Myeloma Using Teclistamab-Daratumumab Intensification and Talquetamab-Daratumumab Early Rescue Intervention

Paula Rodriguez-Otero, Enrique M. Ocio, Albert Oriol, Eusebio Martin, Marta Sonia Gonzalez-Perez, María José Moreno, Mario Arnao, Laura Rosiñol, Roberto Maldonado, Joaquin Martínez-López, Joan Bladé, Juan Jose Lahuerta, Guntug Gungor, Diptendu Santra, Pavel Smirnov, Margaret Doyle, Svetlana Gavrilov, Maria Victoria Mateos, Jesus F. San Miguel

This document will be available on Sep 26th 2026

Outcomes of Outpatient Step‑Up Dosing (SUD) of Teclistamab (Tec) and Talquetamab (Tal) in Relapsed/Refractory Multiple Myeloma (RRMM): Findings From Academic and Community Practices in the USA

Lisa Raff, Joseph Abrams, Cathryn Barisonek, Kimberly Melgarejo, Brenda Simpson, Vanessa Mirsky, Sibel Blau, Jack Khouri, Douglas Sborov, Binod Dhakal, David Oveisi, Jenny Ahlstrom, Ralph V. Boccia, Joshua Richter, Matthew Pianko, Amir Ali, Baylee Bryan, Jinghua He, Eric Chinaeke, Yuehan Zhang, Maithili Deshpande, Gilbert Ko, Dylan Poris, Tonya Le Blanc, Cindy Varga

This document will be available on Sep 23rd 2026

Outpatient Step-Up Dosing of Teclistamab or Talquetamab With Prophylactic Tocilizumab in Patients With Relapsed/Refractory Multiple Myeloma: Real-World Evidence From a Large US Cancer Center

Cesar Rodriguez, Mohammad Rattu, Alex Lieberman-Cribbin, Allison Lilley, Tianxiang Sheng, Maria Bodea, Sundar Jagannath, Adriana Rossi, Shambavi Richard, Joshua Richter, Hearn Jay Cho, Gurbakhash Kaur, Larysa Sanchez, Santiago Thibaud, Maithili Deshpande, Niodita Gupta-Werner, Ming-hui Tai, Jessica Fowler, Tonya Le Blanc, Shuchita Kaila, Samir Parekh

This document will be available on Sep 23rd 2026

Overall Survival, Progression and Non-Relapse Mortality With Teclistamab Plus Daratumumab (Tec-Dara) vs Dara-Based Triplets in Relapsed/Refractory Multiple Myeloma (RRMM): MajesTEC-3 Post Hoc Analysis

Luciano J. Costa, Nizar J. Bahlis, Aurore Perrot, Ajay K. Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Meletios A. Dimopoulos, Elena Zamagni, Surbhi Sidana, Paula Rodriguez-Otero, Robin Carson, Weili Sun, Kristen Lantz, Anne Seifert, Maria Rubin, Huiling Pei, Maria Victoria Mateos

This document will be available on Sep 24th 2026

Patient-Reported Outcomes (PROs) of Teclistamab-Based Treatment (Tx) in Relapsed/Refractory Multiple Myeloma (RRMM) After 1-3 Lines of Therapy (LOT)

Katja C. Weisel, Eva G. Katz, Marguerite O’Hara, Nina Kim, Margaret Doyle, Tzu-Min Yeh, Maria Rubin, Dai Wang, Weili Sun, Priya Shah, Diogo F. Ramos, Susanne Huschens, Michel Delforge

This document will be available on Sep 24th 2026

Phase 2 Study of Talquetamab (Tal), Daratumumab (D), and Lenalidomide (R) as Induction Therapy in Patients (Pts) With Transplant Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM): MajesTEC-5

Leo Rasche, Niels Weinhold, K. Martin Kortüm, Christoph Schaefers, Stephan Bohl, Christine Riedhammer, Lilli Podola, Uta Bertsch, Johannes Waldschmidt, Stefanie Huhn, Michael Hundemer, Gunhild Mechtersheimer, Elias K. Mai, Florian Bassermann, Mathias Hänel, Hans Salwender, Christoph Heuck, Bas Koster, Elena Ershova, Veronique Vreys, Josephine Khan, Katja Weisel, Hartmut Goldschmidt, Hermann Einsele, Marc S. Raab

This document will be available on Sep 25th 2026

Phase 3 MajesTEC-9: Teclistamab Monotherapy vs Pomalidomide, Bortezomib and Dexamethasone or Carfilzomib and Dexamethasone (PVd/Kd) in Chinese Patients With Relapsed Refractory Multiple Myeloma (RRMM)

Aijun Liao, Zhongjun Xia, Jun Luo, Jie Jin, Weijun Fu, Fengyan Jin, Yafei Wang, Chunyan Sun, Wenming Chen, Gang An, Li Bao, Zhen Cai, Bing Chen, Aili He, Xiaobing Huang, Songfu Jiang, Fei Li, Xin Du, Qianming Wang, Xinchao Luo, Xiaohong Wang, Jianmin Zhuo, Yu Hu

This document will be available on Sep 24th 2026

Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (D) ± Pomalidomide (P) vs D Plus Pom and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3

Peter M. Voorhees, Roberto Mina, Paula Rodríguez Otero, Wenming Chen, María Victoria Mateos, Jian Li, Philippe Moreau, Yael C. Cohen, Chang Ki Min, Thomas Jelinek, Jing Christine Ye, Hila Magen, Samuel M. Rubinstein, Weijun Fu, Vania Hungria, Guldane Cengiz Seval, Joao Samuel Farias, Jakub Radocha, Senem Maral, Mehmet Turgut, Youngil Koh, Jaszianne Tolbert, William Terry, Jiangxiu Zhou, Meral Beksac

This document will be available on Sep 24th 2026

Projecting Functional Cure in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) in the MajesTEC-3 Study of Teclistamab-Daratumumab (Tec-Dara) Using a Mixture Cure Model

Thierry Van Effelterre, Nasuh Buyukkaramikli, Mary Slavcev, Eric Ammann, Margaret Doyle, Weili Sun, Feng Pan

This document will be available on Sep 23rd 2026

Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome and Facilitate Dosing of Talquetamab (Tal) in All Practice Settings in Relapsed/Refractory Multiple Myeloma: Results From MonumenTAL-1

Aurore Perrot, Moshe Gatt, Karim Belhadj-Merzoug, Matthew J. Pianko, Lionel Karlin, Carolina Schinke, Ravi Vij, Sundar Jagannath, Larysa Sanchez, Gareth Morgan, Tomasz Wrobel, Jan Zaucha, Meir Preis, Yael C. Cohen, Paula Barreyro, Bonnie W. Lau, Veronique Vreys, Michela Campagna, Tara Masterson, Jenny Zhang, Christoph Heuck, Xiang Qin, Svetlana Gavrilov, Jaszianne Tolbert, Dominik Dytfeld

This document will be available on Sep 24th 2026

Real-World Efficacy and Safety Outcomes of Talquetamab: An Updated Analysis in Predominantly Community-based Setting

Darren Pan, Rohan Parikh, Ming-Hui Tai, Ibrahim Saber, Jessica Fowler, Caleb Paydar, Oluwabunmi Emidio, Angele Kotomale, Tinu Toms, Monica Ahlquist, Shuchita Kaila, Bruce Feinberg

This document will be available on Sep 23rd 2026

Real-World Outcomes in Smoldering Multiple Myeloma in Europe: Updated Results From the SPARK Study

Francesca Gay, Maria Victoria Mateos, Mamta Garg, Ido Lapidot, Julien Thevenon, Lada Mitchell, Emma Smith, Nichola Erler-Yates, Sandra Ketlzer-Henkel, Thomas Chalopin

This document will be available on Sep 23rd 2026

Real-World Patient Characteristics and Effectiveness of Daratumumab-Based Regimens in First-Line Management of Multiple Myeloma in France : Results From a Sub-Analysis of French EMMY Study

Cyrille Hulin, Bruno Royer, Thomas Chalopin, Julie Gay, Hélène Demarquette, Héloïse Mouton, Véronique Vitry, Marie Pierres, Sophie Vernet, Sebastian Wissel, Julien Thevenon, Laure Vincent, Aurore Perrot, Olivier Decaux

This document will be available on Sep 23rd 2026

Real-World Progression-Free Survival Among Non-Transplanted Newly Diagnosed Multiple Myeloma Patients Initiating Frontline DVRd vs VRd

Reed Friend, Philippe Thompson-Leduc, Anabelle Tardif-Samson, Jinghua He, Eric Chinaeke, Vipin Khare, Xin Yin, Rohan Medhekar, Shuchita Kaila, Matthew J. Pianko

This document will be available on Sep 23rd 2026

Real-World Treatment Patterns and Survival Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) in a MajesTEC-3 Study–Like Population From the US Optum Claims Database

Darren Pan, Niranjana Prasad, Marguerite O’Hara, Eric Ammann, Niodita Gupta-Werner, Margaret Doyle, Sandhya Nair

This document will be available on Sep 24th 2026

Systematizing Expert Multiple Myeloma Consultation in a Large Healthcare System Leads to Better Patient Outcomes: A Pragmatic Implementation Study

Bradley D. Hunter, Heather Black, Jacob Wilkes, Tom Belnap, Prashant Q. Sharma, Kimberly Brunisholz, Andrew Knighton

This document will be available on Sep 25th 2026

Teclistamab Plus Daratumumab (Tec-Dara) Versus Real-World Physician’s Choice of Therapy for Relapsed/Refractory Multiple Myeloma: Comparative Effectiveness Based on an Indirect Treatment Comparison

Luciano J. Costa, Sandhya Nair, Mi Jun Keng, Mary Slavcev, Marguerite O’Hara, Eric Ammann, Margaret Doyle, Niodita Gupta-Werner, Weili Sun, Maria-Victoria Mateos

This document will be available on Sep 25th 2026

The Benefit of Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) on Depth and Durability of Response in the Phase 3 CEPHEUS Trial: Updated Minimal Residual Disease Analysis

Sonja Zweegman, Nizar J. Bahlis, Thierry Facon, Vania Hungria, Christopher P. Venner, Aurore Perrot, Marc Braunstein, Josep M. Marti, Supratik Basu, Yael C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Meral Beksac, Angelo Maiolino, Maria Krevvata, Huiling Pei, Lorena Lopez-Masi, Jaclyn Stanziola, Matteo Loi, Fredrik Borgsten, Melissa Rowe, Saad Z. Usmani

This document will be available on Sep 26th 2026

Timing and Resolution of Talquetamab-Related Dysgeusia in Relapsed/Refractory Multiple Myeloma (RRMM): Longitudinal Waterless Empirical Taste Test and Patient Reported Outcomes Profiles From TALisman

Ajai Chari, Niels W.C.J. van de Donk, Beth Faiman, Junichiro Yuda, Alexa Laheij, Richard L. Doty, James Omel, Larysa Sanchez, Alexander Lin, Herve Sroussi, Mariana Fernandez, Kathleen S. Gray, Svetlana Gavrilov, Boo Messahel, Kasey Bolyard, Keqin Qi, Jenny Zhang, Kelly Kato, Chris Heuck, Mark Wildgust, Lori Parisi, Leo Rasche, Rakesh Popat

This document will be available on Sep 23rd 2026

UK Expert Delphi Consensus on Managing Talquetamab-Associated Oral Side Effects and Weight Loss in Patients With Multiple Myeloma

Grant Mehrjou, Rakesh Popat, Charlotte Pawlyn, Jo Ingram, Craig Jones, Seth Francis-Graham, Noa Chapman, Louisa Burton, Mohamed Lockhat

This document will be available on Sep 23rd 2026

Updated Safety and Efficacy of Ramantamig (Ram; JNJ-5322) at the Recommended Phase 2 Dose (RP2D), Demonstrating Feasibility of Outpatient Dosing (OPD) in Relapsed/Refractory Multiple Myeloma (RRMM)

Jeffrey V. Matous, Cindy Varga, Amrita Y. Krishnan, Monique C. Minnema, Niels W.C.J. van de Donk, Hans C. Lee, Saad Z. Usmani, Gala Vega, Nicolas Kint, Darren Pan, Jing Christine Ye, Laura Rosiñol, Sébastien Anguille, Cyrille Touzeau, Albert Oriol, Paula Rodríguez-Otero, María-Victoria Mateos, Caroline Hodin, Daniel Jonathan, Sangmin Lee, Wilfried Roeloffzen, Rakesh Popat, Larysa Sanchez, Martin Kaiser, Alfred L. Garfall

This document will be available on Sep 24th 2026

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

Connect with us

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

Would you like to clear and leave your conversation? Message history will be lost.

Congress Materials – International Myeloma Society (IMS 2026)

5-Year Sustained Minimal Residual Disease (MRD) Negativity and Survival With Daratumumab Maintenance (D-Maint) in Transplant-Eligible (TE) NDMM: CASSIOPEIA Registry

Cost per Responder for Teclistamab-Daratumumab Versus Daratumumab, Pomalidomide, Dexamethasone (DPd), and Daratumumab, Bortezomib, Dexamethasone (DVd) in Relapsed Refractory Multiple Myeloma Patients

Efficacy and Safety of Daratumumab Plus VCd in Newly Diagnosed Amyloid Light-Chain Amyloidosis With Cardiac Involvement: A Pooled Analysis of Asian Patients From AMY2009 and AMY3001

eMMpower-CART: Real-World Insights Into Early-Line Cilta-Cel Outcomes in Multiple Myeloma (MM)

First Results of a Noninterventional, Prospective, Postauthorization Safety Study (PASS) of Ciltacabtagene Autoleucel (Cilta-Cel) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

Long-Term (≥5-Year) Remission and Survival With Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: CARTITUDE-2 Cohort A

Long-Term Outcomes with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Versus VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) in the Phase 3 PERSEUS Study

Matching-Adjusted Indirect Treatment Comparison of Teclistamab Monotherapy (Tec) vs Belantamab With Pomalidomide and Dexamethasone (BPd) for Early-Line Relapsed or Refractory Multiple Myeloma (RRMM)

Matching-Adjusted Indirect Treatment Comparison of Teclistamab With Daratumumab (Tec-Dara) vs Belantamab With Bortezomib and Dexamethasone (BVd) for Early-Line Relapsed/Refractory Multiple Myeloma

MRD-Guided Frontline T-Cell Redirection Therapy for Newly Diagnosed High-Risk Multiple Myeloma Using Teclistamab-Daratumumab Intensification and Talquetamab-Daratumumab Early Rescue Intervention

Outcomes of Outpatient Step‑Up Dosing (SUD) of Teclistamab (Tec) and Talquetamab (Tal) in Relapsed/Refractory Multiple Myeloma (RRMM): Findings From Academic and Community Practices in the USA

Outpatient Step-Up Dosing of Teclistamab or Talquetamab With Prophylactic Tocilizumab in Patients With Relapsed/Refractory Multiple Myeloma: Real-World Evidence From a Large US Cancer Center

Overall Survival, Progression and Non-Relapse Mortality With Teclistamab Plus Daratumumab (Tec-Dara) vs Dara-Based Triplets in Relapsed/Refractory Multiple Myeloma (RRMM): MajesTEC-3 Post Hoc Analysis

Patient-Reported Outcomes (PROs) of Teclistamab-Based Treatment (Tx) in Relapsed/Refractory Multiple Myeloma (RRMM) After 1-3 Lines of Therapy (LOT)

Phase 2 Study of Talquetamab (Tal), Daratumumab (D), and Lenalidomide (R) as Induction Therapy in Patients (Pts) With Transplant Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM): MajesTEC-5

Phase 3 MajesTEC-9: Teclistamab Monotherapy vs Pomalidomide, Bortezomib and Dexamethasone or Carfilzomib and Dexamethasone (PVd/Kd) in Chinese Patients With Relapsed Refractory Multiple Myeloma (RRMM)

Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (D) ± Pomalidomide (P) vs D Plus Pom and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3

Projecting Functional Cure in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) in the MajesTEC-3 Study of Teclistamab-Daratumumab (Tec-Dara) Using a Mixture Cure Model

Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome and Facilitate Dosing of Talquetamab (Tal) in All Practice Settings in Relapsed/Refractory Multiple Myeloma: Results From MonumenTAL-1

Real-World Efficacy and Safety Outcomes of Talquetamab: An Updated Analysis in Predominantly Community-based Setting

Real-World Outcomes in Smoldering Multiple Myeloma in Europe: Updated Results From the SPARK Study

Real-World Patient Characteristics and Effectiveness of Daratumumab-Based Regimens in First-Line Management of Multiple Myeloma in France : Results From a Sub-Analysis of French EMMY Study

Real-World Progression-Free Survival Among Non-Transplanted Newly Diagnosed Multiple Myeloma Patients Initiating Frontline DVRd vs VRd

Real-World Treatment Patterns and Survival Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) in a MajesTEC-3 Study–Like Population From the US Optum Claims Database

Systematizing Expert Multiple Myeloma Consultation in a Large Healthcare System Leads to Better Patient Outcomes: A Pragmatic Implementation Study

Teclistamab Plus Daratumumab (Tec-Dara) Versus Real-World Physician’s Choice of Therapy for Relapsed/Refractory Multiple Myeloma: Comparative Effectiveness Based on an Indirect Treatment Comparison

The Benefit of Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) on Depth and Durability of Response in the Phase 3 CEPHEUS Trial: Updated Minimal Residual Disease Analysis

Timing and Resolution of Talquetamab-Related Dysgeusia in Relapsed/Refractory Multiple Myeloma (RRMM): Longitudinal Waterless Empirical Taste Test and Patient Reported Outcomes Profiles From TALisman

UK Expert Delphi Consensus on Managing Talquetamab-Associated Oral Side Effects and Weight Loss in Patients With Multiple Myeloma

Updated Safety and Efficacy of Ramantamig (Ram; JNJ-5322) at the Recommended Phase 2 Dose (RP2D), Demonstrating Feasibility of Outpatient Dosing (OPD) in Relapsed/Refractory Multiple Myeloma (RRMM)

Connect with us

Connect with us

Live video

Waiting for agent...

Ready to join